drug · antibody
infliximab biosimilar
Marketedupdated 3mo agoby Xentria Inc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 44 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
targets
Tumor necrosis factor
all catalysts(6)
approval · 6
Apr 21, 2017
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Mar 21, 2019
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Jun 26, 2019
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Jan 27, 2022
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Dec 26, 2023
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Oct 28, 2025
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Trials studying infliximab biosimilar
- —Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
- —Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
- —Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that